Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
The test is the fifth assay on the Solana platform to obtain clearance, and expands the firm's offerings in the women's health market.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The FDA go-ahead marks Quidel's fourth MDx test to receive 510(k) clearance for the Solana platform.
The test runs on the company's Solana instrument, which can process up to 12 patient samples in a 45-minute run.
The test uses the helicase-dependent amplification technology that underpins Quidel's AmpliVue line of molecular assays.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.